{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:54:31Z","timestamp":1793760871019,"version":"4.6.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Fixed-duration venetoclax-rituximab (VenR) in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL) in the phase 3 MURANO trial resulted in superior progression-free survival (PFS) and overall survival (OS) vs bendamustine-rituximab (BR). We report the final analyses of MURANO (median follow-up, 7 years). Patients were randomized to VenR (venetoclax 400 mg daily for 2 years plus monthly rituximab for 6 months; n = 194) or BR (6 months; n = 195). In a substudy, patients with progressive disease (PD) received VenR as retreatment or crossover from BR. At the final data cut (3 August 2022), the median PFS with VenR was 54.7 months vs 17.0 months with BR. The 7-year PFS with VenR was 23.0%. The 7-year OS was 69.6% and 51.0%, respectively. Among VenR-treated patients with undetectable minimal residual disease (MRD; uMRD) and no PD at end of treatment (EOT; n = 83), the median PFS from EOT was 52.5 vs 18.0 months in patients with MRD at EOT (n = 35; P &amp;lt; .0001). Fourteen patients had enduring uMRD. Three distinct mutations in BCL2 in 4 patients were identified. In the substudy, 25 patients were retreated with VenR, and 9 patients crossed over to VenR; the median PFS was 23 and 27 months, and the best overall response rate was 72% and 89%, respectively. At the end of combination treatment (EOCT), after retreatment or crossover, 8 and 6 patients achieved uMRD, respectively. No new safety findings were observed. Overall, these final MURANO analyses support consideration of fixed-duration VenR therapy for patients with relapsed\/refractory CLL. This trial was registered at www.clinicaltrials.gov as #NCT02005471.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025525","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T17:12:07Z","timestamp":1740589927000},"page":"2733-2745","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"first","affiliation":[{"name":"1Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Harrup","sequence":"additional","affiliation":[{"name":"2Department of Cancer and Blood Services, Royal Hobart Hospital and University of Tasmania, Hobart, TAS, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Eichhorst","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Owen","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Hematological Malignancies, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-1589","authenticated-orcid":false,"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"8Department of General Hematology, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"de la Serna","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"Jaeger","sequence":"additional","affiliation":[{"name":"10Division of Haematology and Haemostasis, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-9635","authenticated-orcid":false,"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Montillo","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Department of Onco-Hematology, Niguarda Cancer Center, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Mellink","sequence":"additional","affiliation":[{"name":"13Department of Human Genetics, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-3220","authenticated-orcid":false,"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[{"name":"14Department of Immunology, Erasmus University Medical Center, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"15AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Relja","family":"Popovic","sequence":"additional","affiliation":[{"name":"15AbbVie, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"16Genentech, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-5389","authenticated-orcid":false,"given":"Rosemary","family":"Millen","sequence":"additional","affiliation":[{"name":"17Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Lefebure","sequence":"additional","affiliation":[{"name":"17Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Thadani-Mulero","sequence":"additional","affiliation":[{"name":"17Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Boyer","sequence":"additional","affiliation":[{"name":"17Roche Products Ltd, Welwyn Garden City, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"18Department of Hematology, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025060511214490900_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"25","key":"2025060511214490900_bib2","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"31","key":"2025060511214490900_bib3","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025060511214490900_bib4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/bjh.17994","article-title":"Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I\/II AU-003 study","volume":"196","author":"Cull","year":"2022","journal-title":"Br J Haematol"},{"key":"2025060511214490900_bib5","first-page":"LB1900","article-title":"First interim analysis of alpine study: results of a phase 3 randomized study of zanubrutinib versus ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma [abstract]","author":"Hillmen","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2025060511214490900_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2025060511214490900_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2025060511214490900_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025060511214490900_bib9","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2025060511214490900_bib10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"2025060511214490900_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025060511214490900_bib12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025060511214490900_bib13","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II Pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025060511214490900_bib14","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2025060511214490900_bib15","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"1","key":"2025060511214490900_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.09000.x","article-title":"Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results","volume":"157","author":"Delgado","year":"2012","journal-title":"Br J Haematol"},{"issue":"9747","key":"2025060511214490900_bib17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2025060511214490900_bib18","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood-2007-07-099432","article-title":"Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia","volume":"112","author":"Kujawski","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2025060511214490900_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2019.239947","article-title":"Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study","volume":"106","author":"Leeksma","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2025060511214490900_bib20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2025060511214490900_bib21","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2025060511214490900_bib22","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"22","key":"2025060511214490900_bib23","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025060511214490900_bib24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"B\u00f6ttcher","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025060511214490900_bib25","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"34","key":"2025060511214490900_bib26","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"2025060511214490900_bib27","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2019001077","article-title":"Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2025060511214490900_bib28","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2025060511214490900_bib29","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1080\/10428194.2022.2098291","article-title":"Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-targeted therapies in patients with CLL","volume":"63","author":"Wierda","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025060511214490900_bib30","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/HS9.0000000000000287","article-title":"Minimal residual disease assessment in CLL: ready for use in clinical routine?","volume":"3","author":"F\u00fcrstenau","year":"2019","journal-title":"Hemasphere"},{"issue":"4","key":"2025060511214490900_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025060511214490900_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2025060511214490900_bib33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025060511214490900_bib34","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"suppl 1","key":"2025060511214490900_bib35","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2021-147731","article-title":"Assessment of the clonal dynamics of acquired mutations in patients (Pts) with relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) treated in the randomized phase 3 Murano trial supports venetoclax-rituximab (VenR) fixed-duration combination treatment (Tx) [abstract]","volume":"138","author":"Seymour","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025060511214490900_bib36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"2025060511214490900_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/10428194.2019.1660974","article-title":"Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease","volume":"61","author":"Blombery","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025060511214490900_bib38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"issue":"S1","key":"2025060511214490900_bib39","first-page":"1172","article-title":"Retreatment with venetoclax and rituximab combination following disease progression while off therapy in patients with chronic lymphocytic leukemia [abstract]","volume":"8","author":"Brander","year":"2024","journal-title":"HemaSphere"},{"issue":"15","key":"2025060511214490900_bib40","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"2025060511214490900_bib41","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2025060511214490900_bib42","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood.2020004782","article-title":"BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax","volume":"135","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"2025060511214490900_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.HS9.0000845560.07338.2d","article-title":"Fixed-duration (FD) ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 3-year follow-up from the phase 2 captivate study FD cohort [abstract]","volume":"6","author":"Moreno","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2025060511214490900_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2023-187128","article-title":"Relapse after first-line fixed duration ibrutinib + venetoclax: high response rates to ibrutinib retreatment and absence of BTK mutations in patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) with up to 5 years of follow-up in the phase 2 captivate study [abstract]","volume":"142","author":"Ghia","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025060511214490900_bib45","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"2025060511214490900_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-022-00721-6","article-title":"Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024025525\/2378111\/blood_bld-2024-025525-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024025525\/2378111\/blood_bld-2024-025525-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:21:54Z","timestamp":1749136914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/23\/2733\/535766\/The-MURANO-study-final-analysis-and-retreatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":46,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025525","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,5]]},"published":{"date-parts":[[2025,6,5]]}}}